Marien-Hospital Wesel gGmbH

The department is evaluating new treatment strategies for patients with advanced adenocarcinoma of the stomach and gastro‑esophageal junction. The focus is on improving overall survival and response rates.

• Comparison of ramucirumab‑based regimens
• Assessment of overall survival outcomes
• Objective response rate measurement

Marien‑Hospital Wesel gGmbH supports these investigations to advance therapeutic options for gastrointestinal cancers.

Research is focused on maintenance therapy with a targeted inhibitor after standard chemotherapy for cholangiocarcinoma carrying an IDH1 mutation. The aim is to extend disease‑free intervals for patients treated with curative intent.

• Ivosidenib maintenance evaluation
• Sequencing after adjuvant chemotherapy
• Curative‑intent outcome analysis

The site’s oncology team collaborates closely with national cancer networks to bring innovative treatments to the region.

A long‑term safety extension study gathers data on enzyme replacement for children with metachromatic leukodystrophy. Researchers are monitoring neurological function and tolerability over extended periods.

• Intrathecal enzyme delivery assessment
• Extended safety monitoring
• Impact on disease progression

Marien‑Hospital Wesel gGmbH provides a specialized pediatric neurology unit for these rare metabolic disorders.

A pediatric trial tests an oral bacterial lysate to reduce recurrent respiratory infections and wheezing episodes in young children. The primary goal is to lower the number of infections during the treatment year.

• OM 85 efficacy assessment
• Reduction of RTI frequency
• Evaluation of short‑ and long‑term outcomes

The internal medicine department leverages its expertise in pediatric pulmonology to improve child health outcomes.

A preventive study examines whether regular use of a moisturizing cream can lower the incidence of atopic dermatitis in infants at high familial risk. Success is defined by a reduced incidence at six months.

• Moisturizer preventive effect evaluation
• Incidence tracking at six months
• Analysis of high‑risk family cohort

The site’s dermatology team collaborates with pediatric specialists to protect early skin barrier function.